Ignite Creation Date:
2025-12-25 @ 2:36 AM
Ignite Modification Date:
2026-01-08 @ 8:13 PM
Study NCT ID:
NCT00682734
Status:
COMPLETED
Last Update Posted:
2018-05-31
First Post:
2008-05-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Metoclopramide for Migraine: A Dose Finding Study
Sponsor:
Montefiore Medical Center
Organization:
Study Overview
Official Title:
Metoclopramide for Acute Migraine: A Dose Finding Study
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MDFS
Brief Summary:
Metoclopramide is an effective intravenous treatment for acute migraine attacks, but we do not know the best dose to administer. This study compares three different doses of metoclorpamide.
Detailed Description:
Patients with acute migraine attacks are eligible for enrollment if they present to the emergency department of Montefiore Medical Center. Pain scores are assessed at baseline and every 30 minutes for two hours, and then again by telephone 48 hours after discharge
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: